Биологические функции апелинергической системы и ее участие в воспалительных процессах при ревматических заболеваниях

Статья посвящена комплексному анализу современных представлений о роли апелинергической системы в патогенезе ревматических заболеваний. Рассмотрены молекулярные механизмы функционирования системы апелин/APJ и ее участие в ключевых патологических процессах. Особое внимание уделено дисрегуляции данного сигнального пути при различных нозологических формах ревматической патологии, включая ревматоидный артрит, системную красную волчанку, системную склеродермию испондилоартриты. Систематизированы современные данные, устанавливающие взаимосвязь между нарушениями в апелинергической системе и развитием системного воспаления, эндотелиальной дисфункции и фиброзного ремоделирования тканей. Однако некоторые аспекты функционирования системы апелин/APJ остаются недостаточно изученными и требуют дальнейшего исследования. Особую научную значимость представляет уточнение молекулярных основ взаимодействия апелин/APJ с провоспалительными сигнальными путями. На основании последних достижений молекулярной медицины обсуждаются перспективы инновационных подходов к модуляции системы апелин/APJ сприменением биотехнологических методов, открывающих возможность создания новых патогенетических стратегий лечения ревматических заболеваний.

1. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993 Dec 22; 136 (1–2): 355–60. DOI: 10.1016/0378-1119(93)90495-o. PMID: 8294032.

2. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, Osmond DH, George SR, O'Dowd BF. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000 Jan; 74 (1): 34–41. DOI: 10.1046/j.1471-4159.2000.0740034.x. PMID: 10617103.

3. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998 Oct 20; 251 (2): 471–6. DOI: 10.1006/bbrc.1998.9489. PMID: 9792798.

4. Pitkin SL, Maguire JJ, Bonner TI, Davenport AP. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev. 2010 Sep; 62 (3): 331–42. DOI: 10.1124/pr.110.002949. Epub 2010 Jul 6. PMID: 20605969.

5. Zhen EY, Higgs RE, Gutierrez JA. Pyroglutamyl apelin 13 identified as the major apelin isoform in human plasma. Anal Biochem. 2013 Nov 1; 442 (1): 1–9. DOI: 10.1016/j.ab.2013.07.006. Epub 2013 Jul 16. PMID: 23872001.

6. Chng SC, Ho L, Tian J, Reversade B. ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell. 2013 Dec 23; 27 (6): 672–80. DOI: 10.1016/j.devcel.2013.11.002. Epub 2013 Dec 5. PMID: 24316148.

7. Pauli A, Norris ML, Valen E, Chew GL, Gagnon JA, Zimmerman S, Mitchell A, Ma J, Dubrulle J, Reyon D, Tsai SQ, Joung JK, Saghatelian A, Schier AF. Toddler: an embryonic signal that promotes cell movement via Apelin receptors. Science. 2014 Feb 14; 343 (6172): 1248636. DOI: 10.1126/science.1248636. Epub 2014 Jan 9. PMID: 24407481; PMCID: PMC4107353.

8. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]apelin 13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension. 2009 Sep; 54 (3): 598–604. DOI: 10.1161/HYPERTENSIONAHA.109.134619. Epub 2009 Jul 13. PMID: 19597036.

9. Li C, Cheng H, Adhikari BK, Wang S, Yang N, Liu W, Sun J, Wang Y. The Role of Apelin-APJ System in Diabetes and Obesity. Front Endocrinol (Lausanne). 2022 Mar 9; 13: 820002. DOI: 10.3389/fendo.2022.820002. PMID: 35355561; PMCID: PMC8959308.

10. Zhou Q, Chen L, Tang M, Guo Y, Li L. Apelin/APJ system: A novel promising target for anti-aging intervention. Clin Chim Acta. 2018 Dec; 487: 233–240. DOI: 10.1016/j.cca.2018.10.011. Epub 2018 Oct 5. PMID: 30296443.

11. Foris V, Kovacs G, Avian A, Bálint Z, Douschan P, Ghanim B, Klepetko W, Olschewski A, Olschewski H. Apelin 17 to diagnose idiopathic pulmonary arterial hypertension: A biomarker study. Front Physiol. 2023 Jan 4; 13: 986295. DOI: 10.3389/fphys.2022.986295. PMID: 36685176; PMCID: PMC9846527.

12. Girault-Sotias PE, Deloux R, De Mota N, Riché S, Daubeuf F, Iturrioz X, Parlakian A, Berdeaux A, Agbulut O, Bonnet D, Boitard SE, Llorens-Cortes C. The Metabolically Resistant Apelin 17 Analogue LIT01–196 Reduces Cardiac Dysfunction and Remodelling in Heart Failure After Myocardial Infarction. Can J Cardiol. 2025 May; 41 (5): 911–924. DOI: 10.1016/j.cjca.2024.11.034. Epub 2024 Dec 12. PMID: 39674544.

13. Folino A, Montarolo PG, Samaja M, Rastaldo R. Effects of apelin on the cardiovascular system. Heart Fail Rev. 2015 Jul; 20 (4): 505–18. DOI: 10.1007/s10741-015-9475-x. PMID: 25652330.

14. Huang Z, Liu Q, Guo Q, Gao J, Zhang L, Li L. Effects and mechanisms of Apelin in treating central nervous system diseases. Neuroscience. 2025 Feb 6; 566: 177–189. DOI: 10.1016/j.neuroscience.2024.12.025. Epub 2024 Dec 15. PMID: 39681256.

15. Onalan E, Doğan Y, Onalan E, Gozel N, Buran I, Donder E. Elabela levels in patients with type 2 diabetes: can it be a marker for diabetic nephropathy? Afr Health Sci. 2020 Jun; 20 (2): 833–840. DOI: 10.4314/ahs.v20i2.37. PMID: 33163050; PMCID: PMC7609116.

16. Wang X, Liang G, Guo Q, Cai W, Zhang X, Ni J, Tao Y, Niu X, Chen S. ELABELA improves endothelial cell function via the ELA-APJ axis by activating the PI3K/Akt signalling pathway in HUVECs and EA.hy926 cells. Clin Exp Pharmacol Physiol. 2020 Dec; 47 (12): 1953–1964. DOI: 10.1111/1440-1681.13382. Epub 2020 Aug 6. PMID: 32687618.

17. Masri B, Morin N, Pedebernade L, Knibiehler B, Audigier Y. The apelin receptor is coupled to Gi1 or Gi2 protein and is differentially desensitized by apelin fragments. J Biol Chem. 2006 Jul 7; 281 (27): 18317–26. DOI: 10.1074/jbc.M600606200. Epub 2006 May 5. PMID: 16679320.

18. Guo L, Li Q, Wang W, Yu P, Pan H, Li P, Sun Y, Zhang J. Apelin inhibits insulin secretion in pancreatic beta-cells by activation of PI3-kinase-phosphodiesterase 3B. Endocr Res. 2009; 34 (4): 142–54. DOI: 10.3109/07435800903287079. PMID: 19878074.

19. Than A, Zhang X, Leow MK, Poh CL, Chong SK, Chen P. Apelin attenuates oxidative stress in human adipocytes. J Biol Chem. 2014 Feb 7; 289 (6): 3763–74. DOI: 10.1074/jbc.M113.526210. Epub 2013 Dec 20. PMID: 24362107; PMCID: PMC3916573.

20. Chen K, Ou B, Huang Q, Deng D, Xiang Y, Hu F. LncRNA NEAT1 aggravates human microvascular endothelial cell injury by inhibiting the Apelin/Nrf2/HO 1 signalling pathway in type 2 diabetes mellitus with obstructive sleep apnoea. Epigenetics. 2024 Dec; 19 (1): 2293409. DOI: 10.1080/15592294.2023.2293409. Epub 2024 Jan 17. PMID: 38232183; PMCID: PMC10795783.

21. Chang TK, Zhong YH, Liu SC, Huang CC, Tsai CH, Lee HP, Wang SW, Hsu CJ, Tang CH. Apelin Promotes Endothelial Progenitor Cell Angiogenesis in Rheumatoid Arthritis Disease via the miR 525–5p/Angiopoietin 1 Pathway. Front Immunol. 2021 Sep 29; 12: 737990. DOI: 10.3389/fimmu.2021.737990. PMID: 34659230; PMCID: PMC8511637.

22. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999 Aug 6; 85 (3): 221–8. DOI: 10.1161/01.res.85.3.221. PMID: 10436164.

23. Brindle NP, Saharinen P, Alitalo K. Signaling and functions of angiopoietin 1 in vascular protection. Circ Res. 2006 Apr 28; 98 (8): 1014–23. DOI: 10.1161/01.RES.0000218275.54089.12. PMID: 16645151; PMCID: PMC2270395.

24. Chang TK, Zhong YH, Liu SC, Huang CC, Tsai CH, Lee HP, Wang SW, Hsu CJ, Tang CH. Apelin Promotes Endothelial Progenitor Cell Angiogenesis in Rheumatoid Arthritis Disease via the miR 525–5p/Angiopoietin 1 Pathway. Front Immunol. 2021 Sep 29; 12: 737990. DOI: 10.3389/fimmu.2021.737990. PMID: 34659230; PMCID: PMC8511637.

25. Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015 Jul; 11 (7): 390–400. DOI: 10.1038/nrrheum.2015.40. Epub 2015 Mar 31. PMID: 25825281.

26. Drosos AA, Venetsanopoulou AA, Pelechas E, Voulgari PV. Exploring Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis. Eur J Intern Med. 2024 Oct; 128: 1–9. DOI: 10.1016/j.ejim.2024.07.016. Epub 2024 Jul 23. PMID: 39048336.

27. Gunter S, Solomon A, Tsang L, Woodiwiss AJ, Robinson C, Millen AM, Norton GR, Dessein PH. Apelin concentrations are associated with altered atherosclerotic plaque stability mediator levels and atherosclerosis in rheumatoid arthritis. Atherosclerosis. 2017 Jan; 256: 75–81. DOI: 10.1016/j.atherosclerosis.2016.11.024. Epub 2016 Nov 24. PMID: 28017911.

28. Gunter S, Robinson C, Norton GR, Woodiwiss AJ, Tsang L, Millen AME, Dessein PH. Disease severity impacts the relationship of apelin with arterial function in patients with rheumatoid arthritis. Clin Rheumatol. 2018 Jun; 37 (6): 1481–1491. DOI: 10.1007/s10067-018-4013-6. Epub 2018 Feb 8. PMID: 29423718.

29. Di Franco M, Spinelli FR, Metere A, Gerardi MC, Conti V, Boccalini F, Iannuccelli C, Ciciarello F, Agati L, Valesini G. Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis. Mediators Inflamm. 2012; 2012: 347268. DOI: 10.1155/2012/347268. Epub 2012 Aug 7. PMID: 22927708; PMCID: PMC3420101.

30. Wahba AS, Ibrahim ME, Abo-Elmatty DM, Mehanna ET. Association of the Adipokines Chemerin, Apelin, Vaspin and Omentin and Their Functional Genetic Variants with Rheumatoid Arthritis. J Pers Med. 2021 Sep 29; 11 (10): 976. DOI: 10.3390/jpm11100976. PMID: 34683117; PMCID: PMC8539350.

31. Rosendahl AH, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci. 2022 Mar; 38 (3): 187–195. DOI: 10.1002/kjm2.12505. Epub 2022 Mar 2. PMID: 35234358; PMCID: PMC11896191.

32. Huang S, Chen L, Lu L, Li L. The apelin-APJ axis: A novel potential therapeutic target for organ fibrosis. Clin Chim Acta. 2016 May 1; 456: 81–88. DOI: 10.1016/j.cca.2016.02.025. Epub 2016 Mar 2. PMID: 26944568.

33. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 2010 Aug; 7 (8): 425–36. DOI: 10.1038/nrgastro.2010.97. Epub 2010 Jun 29. PMID: 20585339.

34. Pchejetski D, Foussal C, Alfarano C, Lairez O, Calise D, Guilbeau-Frugier C, Schaak S, Seguelas MH, Wanecq E, Valet P, Parini A, Kunduzova O. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J. 2012 Sep; 33 (18): 2360–9. DOI: 10.1093/eurheartj/ehr389. Epub 2011 Oct 25. PMID: 22028387.

35. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med. 2007 Nov 8; 357 (19): 1946–55. DOI: 10.1056/NEJMra067279. PMID: 17989387.

36. Visser YP, Walther FJ, Laghmani el H, Laarse Av, Wagenaar GT. Apelin attenuates hyperoxic lung and heart injury in neonatal rats. Am J Respir Crit Care Med. 2010 Nov 15; 182 (10): 1239–50. DOI: 10.1164/rccm.200909–1361OC. Epub 2010 Jul 9. PMID: 20622042; PMCID: PMC3001263.

37. Fan XF, Xue F, Zhang YQ, Xing XP, Liu H, Mao SZ, Kong XX, Gao YQ, Liu SF, Gong YS. The Apelin-APJ axis is an endogenous counterinjury mechanism in experimental acute lung injury. Chest. 2015 Apr; 147 (4): 969–978. DOI: 10.1378/chest.14-1426. PMID: 25375801.

38. Wang H, Cong L, Yin X, Zhang N, Zhu M, Sun T, Fan J, Xue F, Fan X, Gong Y. The Apelin-APJ axis alleviates LPS-induced pulmonary fibrosis and endothelial mesenchymal transformation in mice by promoting Angiotensin-Converting Enzyme 2. Cell Signal. 2022 Oct; 98: 110418. DOI: 10.1016/j.cellsig.2022.110418. Epub 2022 Jul 23. PMID: 35882286.

39. Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S, Friis-Hansen L. Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept. 2006 Jan 15; 133 (1–3): 134–8. DOI: 10.1016/j.regpep.2005.09.032. Epub 2005 Nov 2. PMID: 16263185.

40. Chandra SM, Razavi H, Kim J, Agrawal R, Kundu RK, de Jesus Perez V, Zamanian RT, Quertermous T, Chun HJ. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2011 Apr; 31 (4): 814–20. DOI: 10.1161/ATVBAHA.110.219980. Epub 2011 Jan 13. PMID: 21233449; PMCID: PMC3113525.

41. Wang Q, Wang GQ, Pang LX, Xue F, Chen XY, Chen R, Kong XX, Gong YS, Fan XF. Changes of apelin and its receptor in lung tissue of rats with pulmonary hypertension induced by monocrotaline. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2013 Mar; 29 (2): 101–5. Chinese. PMID: 23833956.

42. Wang LY, Diao ZL, Zhang DL, Zheng JF, Zhang QD, Ding JX, Liu WH. The regulatory peptide apelin: a novel inhibitor of renal interstitial fibrosis. Amino Acids. 2014 Dec; 46 (12): 2693–704. DOI: 10.1007/s00726-014-1826-8. Epub 2014 Aug 28. PMID: 25164121.

43. Wang LY, Diao ZL, Zheng JF, Wu YR, Zhang QD, Liu WH. Apelin attenuates TGF-β1-induced epithelial to mesenchymal transition via activation of PKC-ε in human renal tubular epithelial cells. Peptides. 2017 Oct; 96: 44–52. DOI: 10.1016/j.peptides.2017.08.006. Epub 2017 Aug 25. PMID: 28847490.

44. Malyszko J, Malyszko JS, Pawlak K, Wolczynski S, Mysliwiec M. Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Transplant Proc. 2008 Dec; 40 (10): 3466–9. DOI: 10.1016/j.transproceed.2008.06.059. PMID: 19100414.

45. Yokoyama Y, Sekiguchi A, Fujiwara C, Uchiyama A, Uehara A, Ogino S, Torii R, Ishikawa O, Motegi SI. Inhibitory Regulation of Skin Fibrosis in Systemic Sclerosis by Apelin/APJ Signaling. Arthritis Rheumatol. 2018 Oct; 70 (10): 1661–1672. DOI: 10.1002/art.40533. Epub 2018 Aug 23. PMID: 29676521.

46. Niemczyk A, Waśkiel-Burnat A, Zaremba M, Czuwara J, Rudnicka L. The profile of adipokines associated with fibrosis and impaired microcirculation in systemic sclerosis. Adv Med Sci. 2023 Sep; 68 (2): 298–305. DOI: 10.1016/j.advms.2023.09.001. Epub 2023 Sep 9. PMID: 37696138.

47. Aozasa N, Hatano M, Saigusa R, Nakamura K, Takahashi T, Toyama T, Sumida H, Tamaki Z, Maki H, Minatsuki S, Komuro I, Sato S, Asano Y. Clinical significance of endothelial vasodilatory function evaluated by EndoPAT in patients with systemic sclerosis. J Dermatol. 2020 Jun; 47 (6): 609–614. DOI: 10.1111/1346–8138.15334. Epub 2020 Mar 30. PMID: 32232898.

48. Andersen CU, Hilberg O, Mellemkjær S, Nielsen-Kudsk JE, Simonsen U. Apelin and pulmonary hypertension. Pulm Circ. 2011 Jul-Sep; 1 (3): 334–46. DOI: 10.4103/2045-8932.87299. PMID: 22140623; PMCID: PMC3224425.

49. Zhang C, Gao C, Di X, Cui S, Liang W, Sun W, Yao M, Liu S, Zheng Z. Hsa_circ_0123190 acts as a competitive endogenous RNA to regulate APLNR expression by sponging hsa-miR 483–3p in lupus nephritis. Arthritis Res Ther. 2021 Jan 13; 23 (1): 24. DOI: 10.1186/s13075-020-02404-8. PMID: 33436040; PMCID: PMC7805051.

50. Genre F, Miranda-Filloy JA, López-Mejias R, Carnero-López B, Ochoa R, Rueda J, González-Juanatey C, Blanco R, Llorca J, González-Gay MA. Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol. 2013 Jul-Aug; 31 (4): 532–7. Epub 2013 Mar 13. PMID: 23484462.

51. Capo A, Di Nicola M, Costantini E, Reale M, Amerio P. Circulating levels of Apelin 36 in patients with mild to moderate psoriasis. G Ital Dermatol Venereol. 2020 Oct; 155 (5): 646–651. DOI: 10.23736/S0392-0488.18.05981–3. Epub 2018 May 10. PMID: 29747483.